Annals of Oncology

Immunomodulation in colorectal cancer: disappointment or promise?
pp. 349-351(3)
Authors: G. Pentheroudakis; N. Pavlidis

More on the regulation of tobacco smoke: how we got here and where next
pp. 353-357(5)
Authors: N. Gray; L. T. Kozlowski

Adjuvant therapy of cutaneous melanoma: the interferon debate
pp. 358-365(8)
Author: R. F. Kefford

Primary chemotherapy followed by anterior craniofacial resection and radiotherapy for paranasal cancer
pp. 367-372(6)
Authors: L. Licitra; L. D. Locati; R. Cavina; I. Garassino; F. Mattavelli; N. Pizzi; P. Quattrone; P. Valagussa; L. Gianni; G. Bonadonna; C. L. Solero; G. Cantu

Results of randomised phase II studies comparing S16020 with methotrexate in patients with recurrent head and neck cancer
pp. 373-377(5)
Authors: X. Pivot; A. Awada; D. Gedouin; J. Kerger; F. Rolland; D. Cupissol; F. Caponigro; G. Comella; J. J. Lopez-Pousa; E. Guardiola; B. Giroux; B. Gérard; M. Schneider

Surgical adjuvant therapy of rectal carcinoma: a controlled evaluation of leucovorin, 5-fluorouracil and radiation therapy with or without interferon-2b
pp. 378-382(5)
Authors: C. Gennatas; C. Dardoufas; D. Mouratidou; N. Tsavaris; A. Pouli; G. Androulakis; M. Philippakis; D. Voros; T. Batalis; S. Besbeas; G. Hatzistylianos; J. Katsos; V. Komporozos; N. Legakis; H. Mallas; G. Peros; A. Photopoulos; C. Pisiotis; G. Polymeneas; G. Retalis; L. Samanidis; V. Smyrniotis; A. Stamatiadis; J. Vasiliou; H. Andreadis; J. Papadimitriou

Phase II study of oxaliplatin, 5-fluorouracil and leucovorin in previously platinum-treated patients with advanced gastric cancer
pp. 383-387(5)
Authors: D. Y. Kim; J. H. Kim; S.-H. Lee; T. Y. Kim; D. S. Heo; Y.-J. Bang; N. K. Kim

Treatment of pancreatic cancer with a combination of irinotecan (CPT-11) and gemcitabine: a multicenter phase II study by the Greek Cooperative Group for Pancreatic Cancer
pp. 388-394(7)
Authors: G. P. Stathopoulos; S. K. Rigatos; M. A. Dimopoulos; T. Giannakakis; G. Foutzilas; C. Kouroussis; D. Janninis; G. Aravantinos; N. Androulakis; S. Agelaki; J. G. Stathopoulos; V. Georgoulias

5-Fluorouracil plus leucovorin is an effective adjuvant chemotherapy in curatively resected stage III colon cancer: long-term follow-up results of the adjCCA-01 trial
pp. 395-399(5)
Authors: H. T. Arkenau; A. Bermann; K. Rettig; G. Strohmeyer; R. Porschen; On behalf of the Arbeitsgemeinschaft Gastrointestinale Onkologie>

Cancer physicians’ attitudes toward colorectal cancer follow-up
pp. 400-405(6)
Authors: C. C. Earle; E. Grunfeld; D. Coyle; M. C. Cripps; H. S. Stern

Locally advanced/inflammatory breast cancers treated with intensive epirubicin-based neoadjuvant chemotherapy: are there molecular markers in the primary tumour that predict for 5-year clinical outcome?
pp. 406-413(8)
Authors: H. Bonnefoi; S. Diebold-Berger; P. Therasse; A. Hamilton; M. van de Vijver; G. MacGrogan; L. Shepherd; N. Amaral; C. Duval; R. Drijkoningen; D. Larsimont; M. Piccart

Tamoxifen alone versus adjuvant tamoxifen for operable breast cancer of the elderly: long-term results of the phase III randomized controlled multicenter GRETA trial
pp. 414-420(7)
Authors: G. Mustacchi; R. Ceccherini; S. Milani; A. Pluchinotta; A. De Matteis; L. Maiorino; A. Farris; A. Scanni; F. Sasso; On behalf of the Italian Cooperative Group GRETA>

Communication, quality of life and age: results of a 5-year prospective study in breast cancer patients
pp. 421-427(7)
Authors: J. Kerr; J. Engel; A. Schlesinger-Raab; H. Sauer; D. Hölzel

Correlation of p53 status with outcome of neoadjuvant chemotherapy using paclitaxel and doxorubicin in stage IIIB breast cancer
pp. 428-432(5)
Authors: A. Anelli; R. R. Brentani; A. P. Gadelha; A. Amorim de Albuquerque; F. Soares

A randomized phase II study of alternating and sequential regimens of docetaxel and doxorubicin as first-line chemotherapy for metastatic breast cancer
pp. 433-440(8)
Authors: R. Paridaens; F. Van Aelst; V. Georgoulias; H. Samonnig; V. Cocquyt; C. Zielinski; H. Hausmaninger; P. Willemse; Y. Boudraa; J. Wildiers; C. Ramazeilles; N. Azli

Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group
pp. 441-448(8)
Authors: M. S. Aapro; F. H. van Wijk; G. Bolis; B. Chevallier; M. E. L. van der Burg; A. Poveda; C. F. de Oliveira; S. Tumolo; V. Scotto di Palumbo; M. Piccart; M. Franchi; F. Zanaboni; A. J. Lacave; R. Fontanelli; G. Favalli; P. Zola; J. P. Guastalla; R. Rosso; C. Marth; M. Nooij; M. Presti; C. Scarabelli; T. A. W. Splinter; E. Ploch; L. V. A. Beex; W. ten Bokkel Huinink; M. Forni; M. Melpignano; P. Blake; P. Kerbrat; C. Mendiola; A. Cervantes; A. Goupil; P. G. Harper; C. Madronal; M. Namer; G. Scarfone; J. E. G. M. Stoot; I. Teodorovic; C. Coens; I. Vergote; J. B. Vermorken; On behalf of the European Organisation for Research and Treatment of Cancer EORTC Gynaecological Cancer Group>

Docetaxel and carboplatin is an active regimen in advanced non-small-cell lung cancer: a phase II study in Caucasian and Asian patients
pp. 449-454(6)
Authors: M. J. Millward; M. J. Boyer; M. Lehnert; S. Clarke; D. Rischin; B.-C. Goh; J. Wong; E. McNeil; J. F. Bishop

ALIMTA^® (pemetrexed disodium) as second-line treatment of non-small-cell lung cancer: a phase II study
pp. 455-460(6)
Authors: E. F. Smit; K. Mattson; J. von Pawel; C. Manegold; S. Clarke; P. E. Postmus

Epidermal growth factor-based cancer vaccine for non-small-cell lung cancer therapy
pp. 461-466(6)
Authors: G. Gonzalez; T. Crombet; F. Torres; M. Catala; L. Alfonso; M. Osorio; E. Neninger; B. Garcia; A. Mulet; R. Perez; R. Lage

Soluble intercellular adhesion molecule-1 (s-ICAM-1/s-CD54) in diffuse large B-cell lymphoma: association with clinical characteristics and outcome
pp. 467-474(8)
Authors: M. J. Terol; M. Tormo; J. A. Martinez-Climent; I. Marugan; I. Benet; A. Ferrandez; A. Teruel; R. Ferrer; J. García-Conde

CD34+-selected versus unmanipulated autologous stem cell transplantation in multiple myeloma: impact on dendritic and immune recovery and on complications due to infection
pp. 475-480(6)
Authors: D. Damiani; R. Stocchi; P. Masolini; A. Michelutti; A. Geromin; A. Sperotto; C. Skert; M. Michieli; M. Baccarani; R. Fanin

An open phase I study assessing the feasibility of the triple combination: oxaliplatin plus irinotecan plus leucovorin/ 5-fluorouracil every 2 weeks in patients with advanced solid tumors
pp. 481-489(9)
Authors: M. Ychou; T. Conroy; J. F. Seitz; S. Gourgou; A. Hua; D. Mery-Mignard; A. Kramar

Mortality from major cancer sites in the European Union, 1955–1998
pp. 490-495(6)
Authors: F. Levi; F. Lucchini; E. Negri; P. Boyle; C. La Vecchia

Skin testing and hypersensitivity reactions to oxaliplatin
pp. 497-498(2)
Authors: C. Garufi; A. Cristaudo; B. Vanni; E. Bria; A. M. Aschelter; B. Santucci; E. Terzoli

Reply to Letter to the Editor on “Fertility after treatment for Hodgkin’s disease”, by M. K. Bohlmann, M. von Wolff & T. Strowitzki et al. (Ann Oncol 2003; 14: 499)
pp. 499-a-500(2)
Authors: Z. Blumenfeld; E. J. Dann

Comment on the Symposium article “Fertility after treatment for Hodgkin’s disease”, by Z. Blumenfeld, E. Dann, I. Avivi et al. (Ann Oncol 2002; 13 Suppl 1: 138–147)
pp. 499-499(1)
Authors: M. K. Bohlmann; M. von Wolff; T. Strowitzki

Interaction between paclitaxel and warfarin
pp. 500-500(1)
Authors: M. E. Thompson; M. S. Highley

Severe hepatic toxicity due to thalidomide in relapsed multiple myeloma
pp. 501-502(2)
Authors: A. Trojan; E. Chasse; B. Gay; G. Pichert; C. Taverna

J. Lugton. Communicating with dying people and their relatives
pp. 503-a-504(2)
Author: D. J. T. Wagener

I. Higginson, A. Carr, P. Robinson (eds). Quality of Life
pp. 503-503(1)
Author: M. Tamburini